The latest price target for Arrowhead Pharma (NASDAQ:ARWR) was reported by Bernstein on May 13, 2026. The analyst firm set a price target for $46.00 expecting ARWR to fall to within 12 months (a possible -38.18% downside). 28 analyst firms have reported ratings in the last year.

The latest analyst rating for Arrowhead Pharma (NASDAQ:ARWR) was provided by Bernstein, and Arrowhead Pharma maintained their market perform rating.

The last upgrade for Arrowhead Pharmaceuticals Inc happened on April 21, 2026 when Morgan Stanley raised their price target to $100. Morgan Stanley previously had an equal-weight for Arrowhead Pharmaceuticals Inc.

There is no last downgrade for Arrowhead Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arrowhead Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arrowhead Pharma was filed on May 13, 2026 so you should expect the next rating to be made available sometime around May 13, 2027.

While ratings are subjective and will change, the latest Arrowhead Pharma (ARWR) rating was a maintained with a price target of $35.00 to $46.00. The current price Arrowhead Pharma (ARWR) is trading at is $74.41, which is out of the analyst’s predicted range.